BiotechTube

EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Contraception

Conditions

Contraception, Female Contraception

Trial Timeline

Apr 1, 2004 → Sep 1, 2004

NCT ID
NCT00258076

About EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE

EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE is a phase 1 stage product being developed by Johnson & Johnson for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT00258076. Target conditions include Contraception, Female Contraception.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00258076Phase 1Completed

Competing Products

20 competing products in Contraception

See all competitors
ProductCompanyStageHype Score
Injection CyclofemSun PharmaceuticalPhase 1/2
41
Relugolix Combination TherapySumitomo PharmaPhase 3
77
Transdermal Contraceptive System + Norgestimate-containing oral contraceptives with EEJohnson & JohnsonPre-clinical
23
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
33
norelgestromin + ethinyl estradiolJohnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; triphasil.Johnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; mercilonJohnson & JohnsonPhase 3
77
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
Monophasic or triphasic Oral contraceptive tablet + Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EEJohnson & JohnsonPre-clinical
23
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
33
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
oral ulipristal acetateMerckPhase 1
33
Etonogestrel contraceptive implantMerckApproved
85
Rifampin 600 MGMerckApproved
85
Long Acting Reversible Contraception (LARC)MerckApproved
85
Etonogestrel contraceptive implantMerckApproved
85
Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-AcetatePfizerPre-clinical
22
Sayana PressPfizerApproved
84
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mgPfizerPhase 3
76
Depo-Provera Contraceptive Injection - DP150CIPfizerApproved
84

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85